CAJ | 학술논문

目的：观察帕洛诺司琼对胃癌化学治疗（简称化疗）中重度呕吐的预防作用。方法选择胃癌术后进行化疗的患者86例，随机分为观察组与对照组，每组43例。两组均给予提高免疫力及营养支持，必要时给予解救性止吐治疗；对照组化疗期间静脉注射盐酸昂丹司琼注射液；观察组化疗第1天静脉注射盐酸帕洛诺司琼注射液。结果治疗后，观察组在急性期、延迟期及全期的呕吐控制率均显著高于同期对照组( P﹤0.05)；观察组总有效率为86.05%，明显高于对照组的76.74%( P﹤0.05)。治疗前后，两组患者体重无明显变化（ P﹥0.05）；观察组每日进食量与治疗前无显著变化，对照组则有所降低，与治疗前及同期观察组相比，差异均有统计学意义（ P﹤0.05）；两组卡氏生活质量( KPS )评分较治疗前均升高，且观察组上升幅度大于对照组（ P﹤0.05）。观察组不良反应发生率为13.95%，与对照组的16.28%比较无明显差异( P﹥0.05)。结论帕洛诺司琼预防胃癌化疗患者中重度呕吐，临床疗效好，对急性和延迟性呕吐的预防作用更显著，不影响患者食量且能改善生活质量，化疗期间只需1次给药，患者依从性更高，值得临床推广。
목적：관찰파락낙사경대위암화학치료（간칭화료）중중도구토적예방작용。방법선택위암술후진행화료적환자86례，수궤분위관찰조여대조조，매조43례。량조균급여제고면역력급영양지지，필요시급여해구성지토치료；대조조화료기간정맥주사염산앙단사경주사액；관찰조화료제1천정맥주사염산파락낙사경주사액。결과치료후，관찰조재급성기、연지기급전기적구토공제솔균현저고우동기대조조( P﹤0.05)；관찰조총유효솔위86.05%，명현고우대조조적76.74%( P﹤0.05)。치료전후，량조환자체중무명현변화（ P﹥0.05）；관찰조매일진식량여치료전무현저변화，대조조칙유소강저，여치료전급동기관찰조상비，차이균유통계학의의（ P﹤0.05）；량조잡씨생활질량( KPS )평분교치료전균승고，차관찰조상승폭도대우대조조（ P﹤0.05）。관찰조불량반응발생솔위13.95%，여대조조적16.28%비교무명현차이( P﹥0.05)。결론파락낙사경예방위암화료환자중중도구토，림상료효호，대급성화연지성구토적예방작용경현저，불영향환자식량차능개선생활질량，화료기간지수1차급약，환자의종성경고，치득림상추엄。
Objective To investigate the preventive effect of palonosetron on severe vomiting in gastric cancer chemotherapy. Methods 86 patients with gastric cancer were randomly divided into the observation group and the control group, 43 cases in each group. The two groups were given treatment to improve the immunity and nutritional support, as well as antiemetic treatment if necessary. The control group was given intravenous injection of ondansetron hydrochloride injection during chemotherapy;the observation group was given intra-venous injection of palonosetron hydrochloride injection on the first day of chemotherapy. Results After treatment, the control rate in the acute phase, delayed phase and total control of observation group was significantly higher than those of the control group in the same phase ( P ﹤ 0. 05 ); the total effective rate of the observation group was 86. 05%, which was significantly higher than 76. 74% of the control group ( P ﹤ 0. 05 ) . No significant difference of body mass between the two groups was observed before and after treatment ( P ﹥ 0. 05 );the food intake of the observation group had no significant difference with before treatment, while the control group de-clined with a statistical difference with before treatment and the observation group ( P ﹤ 0. 05 ) . The KPS of the two groups increased, and the observation group increased more significantly ( P ﹤ 0. 05 ) . The incidence rate of adverse reactions in the observation group was 13. 95%, which was not significantly different with 16. 28% of the control group ( P ﹥ 0. 05 ) . Conclusion Palonosetron in the preven-tion of severe vomiting in gastric cancer chemotherapy has good clinical efficacy and more significant effect on acute and delayed vom-iting, does not affect the patient's appetite and can improve the quality of life. With only one drug delivery, it can increase the patients'compliance and is worthy of clinical promotion.